Celebrex News and Research

RSS

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

Licorice may offer a new approach to preventing colorectal cancer

A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.

23 Mar 2009

Vioxx heart risks confirmed in long-term study

The study, an analysis of people who took the arthritis drug carried out by Dr. Robert Bresalier of the M.D. Anderson Cancer Center at the University of Texas, has found Vioxx doubles the risk of strokes and heart attacks.

14 Oct 2008

Lipitor and Celebrex combined may halt prostate cancer

Researchers at Rutgers' Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.

15 Apr 2008

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

Risks of CVD for COX-2 inhibitors lower than previously reported

In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).

27 Feb 2008

Celebrex may disrupt heart rhythm

Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.

25 Jan 2008

Pfizer wins day in court over Celebrex

Drug giant Pfizer has won a court ruling in the United States which could limit the lawsuits the company might possibly face over claims that its painkiller Celebrex caused heart attacks and strokes.

20 Nov 2007

SSRIs may double risk of gastrointestinal bleeding

New research shows that selective serotonin reuptake inhibitors (SSRIs), a group of drugs commonly used to treat depression, may double the risk of gastrointestinal bleeding, according to researchers from Wake Forest University School of Medicine and colleagues.

9 Oct 2007

NanoBio expands drug development team

NanoBio Corporation has announced the addition of four new scientists to its drug development team.

26 Sep 2007

Electronics to the rescue of sloppy doctors

Doctors are famous for sloppy scribbling - and handwritten prescriptions lead to thousands of medication errors each year.

28 Jun 2007

All pain medications may raise risk of heart attack or stroke

Not long ago, choosing a pain reliever meant finding one that eased your pain without being too hard on the stomach.

1 Jun 2007

Researchers look at benefits of aspirin for colon cancer prevention

A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

24 May 2007

Some NSAIDs may be better suited to treating cancer

Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.

18 May 2007

Time for FDA to set the record straight on common painkillers

The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe, says Curt Furberg, M.D., Ph.D., from Wake Forest University School of Medicine.

25 Apr 2007

Four genes found to drive spread of breast cancer to the lungs

Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.

12 Apr 2007

Green tea and COX-2 inhibitors combine to slow growth of prostate cancer

Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.

1 Mar 2007